A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)

Osteoporosis International

Volumn 14, Issue 3, 2003, Pages 225-234

  Shiraki, M ^a   Fukunaga, M ^b   Kushida, K ^c   Kishimoto, H ^d,k   Taketani, Y ^e,l   Minaguchi, H ^f,m   Inoue, T ^c,n   Morita, R ^g   Morii, H ^h   Yamamoto, K ^d,o   Ohashi, Y ⁱ   Orimo, H ^j,p  

^a Research Institute and Practice for Involutional Diseases   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j Ministry of Finance   (Japan)

^k SAN IN ROSAI HOSPITAL   (Japan)

^l UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^m Minaguchi Hospital   (Japan)

ⁿ Aoyama General Hospital   (Japan)

^o Hakuai Hospital   (Japan)

^p Tokyo Metropolitan Institute of Gerontology   (Japan)

more..

Author keywords

Bone mineral density; Dose response; Osteoporosis; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; DEOXYPYRIDINOLINE; OSTEOCALCIN; PHOSPHORUS; PLACEBO; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CALCIUM INTAKE; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; JAPAN; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; NUTRITIONAL DISORDER; OSTEOPOROSIS; PARASITOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STATISTICAL SIGNIFICANCE;

ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 4544222260     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-002-1369-9     Document Type: Article

References (18)

1. Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis, a randomized, controlled trial. J Am Med Assoc 282:1344-1352
2. Reginster J-Y, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
3. Liberman UA, Weiss SR, Broil J et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
4. Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of facture in women with existing vertebral fractures. Lancet 348:1535-1541
5. McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
6. Nakamura T, Kushida K, Shiraki M et al. (1998) A placebo-controlled, double blind study to determine the appropriate alendronate dosage in Japanese patients with involutional osteoporosis, and postmenopausal osteopenia or artificially menopausal women. Med Consult New Remedies 35:3-17 [in Japanese]
7. Shiraki M, Kushida K, Fukunaga M et al. (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10:183-192
8. Kishimoto H, Kushida K, Shiraki M et al. (2002) A clinical trial evaluating the efficacy and safety of risedronate (NE-58095) in patients with involutional osteoporosis or bone mineral content loss associated with lack of ovarian function: early phase II study of NE-58095. Osteoporosis Jpn 10:61-83 [in Japanese]
9. Orimo H, Sugioka Y, Fukunaga M et al. (1995) The Committee of the Japanese Society for Bone and Mineral Research for Development of Diagnostic Criteria of Osteoporosis. Diagnostic criteria of primary osteoporosis. Osteoporosis Jpn 3:669-674 [in Japanese]
10. Brown RC, Aston JP, Weeks I et al. (1987) Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab 65:407-414
11. Eguchi H, Hosoda K, Kurihara N et al. (1995) Sandwich immunoassay specific for the N-terminal sequence of osteocalcin. J Immunol Methods 184:213-240
12. De Leenheer AP, Bauwens RM (1985) Comparison of a cytosol radioreceptor assay with a radioimmunoassay for 1,25-dihydroxyvitamine D in serum or plasma. Clin Chim Acta 152:143-154
13. Black D, Dunkan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal Biochem 169:197-203
14. Fogelman I, Ribot C, Smith R et al. (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895-1900
15. Laboratory of Informatics on Health and Nutrition (1999) Sixth revision of recommended dietary allowances (RDA) for the Japanese: dietary reference intakes. Dai-ichi Shuppan Publishing, Tokyo [in Japanese]
16. Ogura Y, Gonsyo A, Tei M et al. (in press) Phase I clinical trial of risedronate sodium (NE-58095) hydrate: single and multiple oral dose studies. J Bone Miner Metab
17. Mitchell DY, Eusebio RA, Sacco-Gibson NA et al. (2000) Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 40:258-265
18. McClung M, Bensen W, Bolognese M et al. (1998) Risedronate increases bone mineral density at the hip, spine, and radius in postmenopausal women with low bone mass. Osteoporos Int 8 (Suppl 3):111